Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc (SMTI) specializes in advanced collagen-based solutions for surgical and chronic wound care, serving healthcare providers through clinically validated technologies. This hub provides investors and medical professionals with centralized access to official corporate developments.
Key Resources: Track FDA clearances for medical devices, quarterly earnings reports detailing commercialization progress, and strategic partnership announcements with healthcare distributors. All content is sourced directly from company filings and verified press releases.
Content Types Include: Product launch details for wound care innovations, financial performance updates, clinical study outcomes, and executive leadership changes. Materials are organized chronologically for historical analysis and trend identification.
Staying Informed: Bookmark this page or check regularly for unedited primary source materials about SMTI's market position in medical technology. Cross-reference with regulatory databases for complete context on product approvals.
Sanara MedTech Inc. (NASDAQ: SMTI) has received 510(k) clearance for its BIASURGE™ Advanced Surgical Solution, marking a significant milestone in its growth strategy. This patented composition is designed for mechanical cleansing and removal of debris from wounds, aiming to improve clinical outcomes and reduce healthcare costs. The product is set to be commercially available in late 2023. CEO Zach Fleming highlighted the importance of this clearance as part of the company's efforts to expand its product offerings in the surgical market, emphasizing the capabilities of Sanara's research and development team.
Sanara MedTech Inc (NASDAQ: SMTI) reported its 2022 financial results, achieving a 90% increase in net revenues to $45.8 million compared to $24.1 million in 2021. Key factors include expanding sales of its CellerateRX product line, which was sold in over 700 facilities across 29 states. Sanara generated over $5 million in revenue in a single month for the first time. However, the company reported a net loss of $8.1 million for 2022, slightly higher than $8.0 million in 2021. SG&A expenses rose significantly to $46.0 million, and R&D expenses increased to $3.4 million. Sanara plans further growth through strategic partnerships and product launches.
FAQ
What is the current stock price of Sanara Medtech (SMTI)?
What is the market cap of Sanara Medtech (SMTI)?
